[Study of extrapyramidal manifestations induced by neuroleptics].
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D004357:Drug Synergism; D005116:Extrapyramidal Tracts; D005476:Fluphenazine / Q000009:adverse effects; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D008728:Methotrimeprazine / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced* / Q000517:prevention & control; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use; D011395:Promazine / Q000009:adverse effects; D012110:Reserpine / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000009:adverse effects*; D014268:Trifluoperazine / Q000009:adverse effects / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use
D000978:Antiparkinson Agents; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D014282:Trihexyphenidyl; D012110:Reserpine; D008728:Methotrimeprazine; D006220:Haloperidol; D011395:Promazine; D005476:Fluphenazine; D002746:Chlorpromazine
Etude des manifestations extra-pyramidales induites par les neuroleptiques.